To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

ConditionRett Syndrome
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age5-20
SponsorBiomed Industries, Inc.

About this trial

Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome

Key Secondary Objective

• To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female subjects 5 to 20 years of age, inclusive, at Screening

Body weight ≥12 kg at Screening

Can swallow the study medication provided as a liquid solution or can take it by gastrostomy tube

Has classic/typical Rett syndrome (RTT)

Disqualifiers

Has been treated with insulin within 12 weeks of Baseline

Has current clinically significant cardiovascular, endocrine (such as hypo- or hyperthyroidism, Type 1 diabetes mellitus, or uncontrolled Type 2 diabetes mellitus), renal, hepatic, respiratory or gastrointestinal disease (such as celiac disease or inflammatory bowel disease) or has major surgery planned during the study

Has a history of, or current, cerebrovascular disease or brain trauma

Has significant, uncorrected visual or uncorrected hearing impairment

Trial design

Design model

Parallel

Treatments tested in this trial

  • Bionetide

    Drug

    Bionetide solution of 20-40 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)

  • Placebo

    Drug

    Placebo • Bionetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks

Treatment groups

210 Participants
are divided into 2 treatment groups
Group A: BionetideExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Rett Syndrome Behavior Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12

The RSBQ is a 45-item caregiver-completed rating scale that includes 45 items, 39 of them grouped into 8 subscales, whose ratings reflect the severity and frequency of symptoms. Items are rated as 0 (not true), 1 (somewhat or sometimes true), or 2 (very true). The 8 subscales are general mood, breathing problems, hand behavior, face movements, body rocking/expressionless face, night-time behaviors, fear/anxiety, and walking/standing. Scores for item 31 are reversed in the calculation of the total score. The total score ranges from 0 to 90 and is calculated as the sum of the item scores. Higher scores mean worse behavior.

Time frame
Baseline and Week 12
2

Clinical Global Impression-Improvement (CGI-I) Score at Week 12

To rate how much the subject's illness has improved or worsened relative to a baseline state, a 7-point scale is used from 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.

Time frame
12 Weeks Treatment Duration

Secondary outcomes

1

Change From Baseline to Week 12 in Communication and Symbolic Behavior Scales Developmental

Standardized screening scale for assessing communication and pre-linguistic skills in young children 12-24 months and can be used with older children with developmental delay. The CSBS-DP includes a suite of three separate measures: The Infant-Toddler Checklist, a follow-up Caregiver Questionnaire and a Behavior Sample. In this study only the Infant-Toddler (CSBS-DP-IT) Checklist was used. The CSBS-DP-IT Checklist is a 24-item rating scale and each item is scored using a three-level rating of frequency: "not yet", "sometimes" and "often". The CSBS-DP-IT Social Composite score the range was 0 to 26 and a higher score represented a worse outcome. Three composite scores can be calculated: 1) Social Composite; 2) Speech Composite; 3) Symbolic Composite.

Time frame
12 Weeks Treatment Duration
2

Change From Baseline to Week 12 in Impact of Childhood Neurologic Disability Scale (ICND) Total Score

The Impact of Childhood Neurologic Disability (ICND) scale evaluates the effect of four conditions or health problems on 11 aspects of a child's or family's life as "A lot", "Some", "A little", "Not at all", or "Does not apply". The four conditions or health problems are 1) inattentiveness, impulsivity, or mood, 2) ability to think and remember, 3) neurologic or physical limitations, and 4) epilepsy. The ICND score the range of 0 to 132 and a higher score represents a worse outcome.

Time frame
12 Weeks Treatment Duration
3

Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Hand Function (RTT-HF)

Clinical assessment of the subject's ability to use their hands for functional purposes (such as reaching for and grasping objects, self-feeding, or drawing). The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment.

Time frame
12 Weeks Treatment Duration
4

Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Ambulation and Gross Motor Skills (RTT-AMB)

Clinical assessment of the subject's ability to sit, stand, and ambulate (e.g., walking, running, and climbing stairs). The assessment was made on an 8-point Likert scale (0 to 7), with 0 denoting normal functioning and 7 as the most severe impairment.

Time frame
12 Weeks Treatment Duration

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Biomed Industries, Inc.

Lead sponsor

Bioneurals Ltd

Collaborator